Meaningful patient representation takes more than a seat at the table. Committees deciding which medicines health plans cover need both supported patient participation and routine consideration of evidence about patients’ experiences.
Reservoir’s Elisabeth Oehrlein and Joe Vandigo coauthored a Health Affairs Forefront article with Marc Boutin of the Innovation and Value Initiative, Stephen Taylor of the Arthritis Foundation, and Kimberly Westrich of the National Pharmaceutical Council. The authors examine what meaningful patient representation requires.
Why it matters:
Patients bring real-life insights into treatment burden, affordability and coverage barriers that clinical and economic data may not capture. Meaningful representation requires both support for patients to contribute and routine consideration of patient experience evidence. Together, these can help committees make coverage decisions that better reflect what matters to patients and families.
The context:
Health plans subject to the essential health benefits prescription drug requirements must include at least one patient representative on their pharmacy and therapeutics (P&T) committees as of January 1, 2026.
Zoom in:
The authors of the Health Affairs Forefront article identify four priorities for implementation:
- Select and support patient representatives. Choose people who bring lived experience and an understanding of the wider patient community. Use transparent selection criteria, orientation, clear participation expectations and conflict-of-interest policies.
- Review patient experience evidence routinely. One person cannot represent every experience. Committees should review research with patients and caregivers alongside clinical, economic and real-world evidence, with representatives helping interpret findings and identify gaps.
- Broaden how value is considered. Include treatment burden, daily functioning, financial strain, patient time and effects on caregivers and households alongside effectiveness, safety and cost.
- Evaluate influence on decisions. Assess whether patient participation and evidence shape formulary review and utilization management and help identify barriers to starting and staying on treatment.
The key distinction:
Patient representatives bring lived experience and judgment to committee discussions. Research with patients and caregivers can show where experiences differ and which concerns extend across a community. Representatives can help interpret that evidence and identify perspectives that are missing. Committees need both to understand how coverage decisions affect patients and families.
Bottom Line:
Success depends on whether patients’ perspectives influence the discussion and the decisions that follow.
That requires attention to both how patients participate and how patient experience evidence is considered.
Go deeper:
For more information, contact Elisabeth Oehrlein.


.png)

